L-315-2019

Agreement ID
L-315-2019
Lead IC
NIBIB
Exclusivity
Exclusive
External Party
Molecular Targeting Technologies, Inc
Fiscal Year
2020
Territory
Worldwide
Execution Date
Effective Date
Export Date
Technologies
TAB-4585     Radiotherapy and Imaging Agent-based on Peptide Conjugated to Novel Evans Blue Derivatives with Long Half-life and High Accumulation in Target Tissue